| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| CJMBCALLAN JMB INC. | 19.42M | 4.20 | -4.83 | -50.29% | -112.68% | -159.6% | 2.55% | 0.29 |
| CYRXCryoport, Inc. | 564.28M | 11.27 | -5.10 | -1.7% | 35.52% | 13.11% | 0.62 | |
| HKPDHong Kong Pharma Digital Technology Holdings Limited | 8.77M | 0.80 | -265.67 | 21.72% | -0.13% | -0.59% | 4.72% | 0.48 |
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Sales/Revenue | 12.56M | 16.69M | 20.31M |
| Revenue Growth % | - | 0.33% | 0.22% |
| Cost of Goods Sold | 9.82M | 13.13M | 17.9M |
| COGS % of Revenue | 0.78% | 0.79% | 0.88% |
| Gross Profit | 2.74M | 3.56M | 2.42M |
| Gross Margin % | 0.22% | 0.21% | 0.12% |
| Gross Profit Growth % | - | 0.3% | -0.32% |
| Operating Expenses | 1.7M | 1.95M | 2.28M |
| OpEx % of Revenue | 0.14% | 0.12% | 0.11% |
| Selling, General & Admin | 1.76M | 1.89M | 2.22M |
| SG&A % of Revenue | 0.14% | 0.11% | 0.11% |
| Research & Development | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - |
| Other Operating Expenses | -62.95K | 60.95K | 67.26K |
| Operating Income | 1.04M | 1.61M | 132.04K |
| Operating Margin % | 0.08% | 0.1% | 0.01% |
| Operating Income Growth % | - | 0.54% | -0.92% |
| EBITDA | 1.76M | 2.53M | 1.21M |
| EBITDA Margin % | 0.14% | 0.15% | 0.06% |
| EBITDA Growth % | - | 0.44% | -0.52% |
| D&A (Non-Cash Add-back) | 714.59K | 925.58K | 1.07M |
| EBIT | 1.04M | 1.61M | 133.78K |
| Net Interest Income | -23.02K | -82.29K | -95.93K |
| Interest Income | 219 | 474 | 1.74K |
| Interest Expense | 23.24K | 82.77K | 97.67K |
| Other Income/Expense | -23.02K | -82.29K | -95.93K |
| Pretax Income | 1.02M | 1.53M | 36.11K |
| Pretax Margin % | 0.08% | 0.09% | 0% |
| Income Tax | 22.57K | 196.25K | 63.17K |
| Effective Tax Rate % | 0.98% | 0.87% | -0.75% |
| Net Income | 998.2K | 1.33M | -27.06K |
| Net Margin % | 0.08% | 0.08% | -0% |
| Net Income Growth % | - | 0.33% | -1.02% |
| Net Income (Continuing) | 998.2K | 1.33M | -27.06K |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | 0.09 | 0.18 | -0.00 |
| EPS Growth % | - | 0.98% | -1.02% |
| EPS (Basic) | 0.09 | 0.18 | -0.00 |
| Diluted Shares Outstanding | 11M | 7.37M | 10.21M |
| Basic Shares Outstanding | 11M | 7.37M | 9.02M |
| Dividend Payout Ratio | - | - | - |
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Total Current Assets | 2.75M | 7.8M | 8.73M |
| Cash & Short-Term Investments | 524.61K | 619.58K | 3.01M |
| Cash Only | 524.61K | 619.58K | 748.72K |
| Short-Term Investments | 0 | 0 | 2.26M |
| Accounts Receivable | 1.7M | 3.72M | 4.71M |
| Days Sales Outstanding | 49.35 | 81.33 | 84.69 |
| Inventory | 190.89K | 933.3K | 559.98K |
| Days Inventory Outstanding | 7.1 | 25.95 | 11.42 |
| Other Current Assets | 268.98K | 1.27M | 400 |
| Total Non-Current Assets | 658.29K | 865.52K | 690.17K |
| Property, Plant & Equipment | 654.26K | 833.69K | 593.73K |
| Fixed Asset Turnover | 19.19x | 20.02x | 34.21x |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 4.03K | 31.82K | 96.44K |
| Long-Term Investments | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 |
| Total Assets | 3.41M | 8.67M | 9.42M |
| Asset Turnover | 3.69x | 1.93x | 2.16x |
| Asset Growth % | - | 1.54% | 0.09% |
| Total Current Liabilities | 2.55M | 3.18M | 2.92M |
| Accounts Payable | 1.4M | 1.32M | 1.73M |
| Days Payables Outstanding | 52.08 | 36.78 | 35.23 |
| Short-Term Debt | 62.35K | 215.2K | 371.56K |
| Deferred Revenue (Current) | 268.03K | 191.07K | 124.51K |
| Other Current Liabilities | 0 | 0 | 0 |
| Current Ratio | 1.08x | 2.46x | 2.99x |
| Quick Ratio | 1.00x | 2.16x | 2.80x |
| Cash Conversion Cycle | 4.38 | 70.5 | 60.87 |
| Total Non-Current Liabilities | 271.45K | 1.24M | 1.51M |
| Long-Term Debt | 116.86K | 1.12M | 1.5M |
| Capital Lease Obligations | 154.59K | 117.84K | 6.41K |
| Deferred Tax Liabilities | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 |
| Total Liabilities | 2.82M | 4.41M | 4.43M |
| Total Debt | 691.08K | 2.09M | 2.37M |
| Net Debt | 166.46K | 1.47M | 1.63M |
| Debt / Equity | 1.18x | 0.49x | 0.48x |
| Debt / EBITDA | 0.39x | 0.82x | 1.97x |
| Net Debt / EBITDA | 0.09x | 0.58x | 1.35x |
| Interest Coverage | 44.91x | 19.43x | 1.35x |
| Total Equity | 585.24K | 4.25M | 4.99M |
| Equity Growth % | - | 6.27% | 0.17% |
| Book Value per Share | 0.05 | 0.58 | 0.49 |
| Total Shareholders' Equity | 585.24K | 4.25M | 4.99M |
| Common Stock | 6.84K | 10K | 11K |
| Retained Earnings | 201.39K | 1.53M | 1.5M |
| Treasury Stock | 0 | 0 | 0 |
| Accumulated OCI | -4.34K | -4.86K | 10.82K |
| Minority Interest | 0 | 0 | 0 |
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Cash from Operations | 1.73M | -394.33K | 569.21K |
| Operating CF Margin % | 0.14% | -0.02% | 0.03% |
| Operating CF Growth % | - | -1.23% | 2.44% |
| Net Income | 998.2K | 1.33M | -27.06K |
| Depreciation & Amortization | 714.59K | 925.58K | 1.07M |
| Stock-Based Compensation | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | -708 | 43.15K |
| Working Capital Changes | 14.3K | -2.65M | -520.25K |
| Change in Receivables | -929.51K | -2.09M | -1.02M |
| Change in Inventory | -191.16K | -741.95K | 378.2K |
| Change in Payables | 955.27K | -105.22K | 396.88K |
| Cash from Investing | -132.09K | -40.8K | -2.45M |
| Capital Expenditures | -114.64K | -52.74K | -69.92K |
| CapEx % of Revenue | 0.01% | 0% | 0% |
| Acquisitions | - | - | - |
| Investments | - | - | - |
| Other Investing | -17.45K | 11.94K | -85.07K |
| Cash from Financing | -1.16M | 537.32K | 2M |
| Debt Issued (Net) | - | - | - |
| Equity Issued (Net) | - | - | - |
| Dividends Paid | 0 | 0 | 0 |
| Share Repurchases | - | - | - |
| Other Financing | 0 | -345.22K | -1.38M |
| Net Change in Cash | - | - | - |
| Free Cash Flow | 1.61M | -482.35K | 414.23K |
| FCF Margin % | 0.13% | -0.03% | 0.02% |
| FCF Growth % | - | -1.3% | 1.86% |
| FCF per Share | 0.15 | -0.07 | 0.04 |
| FCF Conversion (FCF/Net Income) | 1.73x | -0.30x | -21.04x |
| Interest Paid | 7.31K | 82.77K | 97.67K |
| Taxes Paid | 0 | 0 | 294.83K |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Return on Equity (ROE) | 170.56% | 54.96% | -0.59% |
| Return on Invested Capital (ROIC) | 104.14% | 37.27% | 1.61% |
| Gross Margin | 21.81% | 21.32% | 11.89% |
| Net Margin | 7.95% | 7.97% | -0.13% |
| Debt / Equity | 1.18x | 0.49x | 0.48x |
| Interest Coverage | 44.91x | 19.43x | 1.35x |
| FCF Conversion | 1.73x | -0.30x | -21.04x |
| Revenue Growth | - | 32.91% | 21.72% |
| 2025 | |
|---|---|
| Supply Chain Services Member | 12.48M |
| Supply Chain Services Member Growth | - |
Hong Kong Pharma Digital Technology Holdings Limited (HKPD) reported $20.3M in revenue for fiscal year 2025. This represents a 62% increase from $12.6M in 2023.
Hong Kong Pharma Digital Technology Holdings Limited (HKPD) grew revenue by 21.7% over the past year. This is strong growth.
Hong Kong Pharma Digital Technology Holdings Limited (HKPD) reported a net loss of $0.0M for fiscal year 2025.
Hong Kong Pharma Digital Technology Holdings Limited (HKPD) has a return on equity (ROE) of -0.6%. Negative ROE indicates the company is unprofitable.
Hong Kong Pharma Digital Technology Holdings Limited (HKPD) generated $0.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.